Skip to main content
SpringerLink
Log in

Targeted-Therapie

Neue Zielstrukturen und Substanzen in der Behandlung maligner Lymphome

Targeted therapy

New targets and substances in the treatment of malignant lymphoma

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Detaillierte Kenntnisse über biologische Grundlagen der Lymphomentstehung haben die Entwicklung von Medikamenten ermöglicht, die zielgerichtet an für das Überleben der Lymphomzellen essenziellen molekularen Strukturen angreifen. Die Einbeziehung dieser Medikamente in die Behandlungskonzepte des Non-Hodgkin-Lymphoms (NHL) wird mit hoher Wahrscheinlichkeit Remissions- und Heilungsraten bei Lymphompatienten verbessern können. Zielstrukturen auf der Zelloberfläche wie das CD20-Antigen wurden als „targets“ bereits erfolgreich in die Therapie eingeführt und erfahren durch Radionuklidmarkierung und Verbesserung der Antikörperstruktur eine Weiterentwicklung. Intrazelluläre Moleküle, die an der Vermittlung des aktiven Zelltods (Apoptose) beteiligt sind, könnten die Wirksamkeit konventioneller Therapien künftig wesentlich steigern.

Abstract

Detailed knowledge of the biological mechanisms of lymphomagenesis has made possible the development of drugs that target molecular structures essential for the survival of lymphoma cells. The integration of these drugs in treatment strategies for lymphomas will increase the remission and cure rates for lymphoma patients in the near future. Target structures on the cell surface, such as the CD20 antigen, have already been introduced into clinical practice with high success rates. Monoclonal antibodies directed against the CD20 antigen will be further improved by radionuclide labeling or modification of the antibody itself. Intracellular molecules involved in the modulation of active cell death will be able to increase the efficacy of conventional chemotherapeutic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Anderson KC, Bates MP, Slaughenhoupt BL et al. (1984) TI-Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63: 1424–1433

    PubMed  Google Scholar 

  2. Chaganti SR, Chen W, Parsa N et al. (1998) Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes. Cancer 23: 323–327

    Google Scholar 

  3. Cheson BD (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101: 391–398

    Article  PubMed  Google Scholar 

  4. Feugier P, van Hoof A, Sebban C et al. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23: 4117–4126

    Article  PubMed  Google Scholar 

  5. Forstpointner R, Dreyling M, Repp R et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104: 3064–3071

    Article  PubMed  Google Scholar 

  6. Ghielmini M, Schmitz SF et al. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103: 4416–4423

    Article  PubMed  Google Scholar 

  7. Hachem A, Gartenhaus RB (2005) TI-Oncogenes as molecular targets in lymphoma. Blood 106: 1911–1923

    Article  PubMed  Google Scholar 

  8. Harris NL et al. (2001) Tumours of Haemotopoietic and Lymphoid Tissue. Blue Book, WHO, 1st en. IARC Press, Lyon

  9. Hengartner MO (2000)The biochemistry of apoptosis. Nature 407: 770–776

    Article  PubMed  Google Scholar 

  10. Herold M et al. (2004) Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL). ASH 2004; abstr. 584

  11. Hiddemann W et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP significantly improves the outcome for patients with andvanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725–3732

    Article  PubMed  Google Scholar 

  12. Korsmeyer SJ (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879–886

    PubMed  Google Scholar 

  13. Kuppers R (2005) Mechanisms of B cell lymphoma pathogenesis. Nat Rev Cancer 5: 251–262

    Article  PubMed  Google Scholar 

  14. Lenz G, Dreyling M, Hoster E et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, Ddoxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984–1992

    Article  PubMed  Google Scholar 

  15. Maloney DG, Liles TM, Czerwinski DK et al. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457–2466

    PubMed  Google Scholar 

  16. Marcus R, Imrie K, Belch A et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417–1423

    Article  PubMed  Google Scholar 

  17. Melnick AM, Adelson K, Licht JD (2005) The theoretical basis of transcriptional therapy of cancer: can it be put in practice? J Clin Oncol 23: 3957–3970

    Article  PubMed  Google Scholar 

  18. Mounier N, Briere J, Gisselbrecht C et al. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279–4284

    Article  PubMed  Google Scholar 

  19. O’Connor OA (2005) new strategies for the treatment of lymphoma. J Clin Oncol 23: 6429–6436

    Article  PubMed  Google Scholar 

  20. Pfreundschuh M, Trümper L, Gill D et al. (2004) First analysis of the completed Mabthera International (MInT) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease. Blood 104: 48a

    Google Scholar 

  21. Rajkumar SV, Richardson PG, Hideshima T et al. (2005) TI-Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630–639

    Article  PubMed  Google Scholar 

  22. Reed JC, Pellecchia M (2005) TI-Apoptosis-based therapies for hematologic malignancies. Blood 106: 408–418

    Article  PubMed  Google Scholar 

  23. Salles GA et al. (2004) Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood ASG Proc; 104(11): 160a

  24. Staudt LM (2003) Molecular Diagnosis of the Hematologic Cancers. N Engl J Med 348: 1777–1785

    Article  PubMed  Google Scholar 

  25. Witzig TE, Gordon LI, Cabanillas F et al. (2002) Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-Cell Non-Hodgkin’s Lymphoma. J Clin Oncol 20: 2453–2463

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Abt. Hämatologie und Onkologie, Zentrum Innere Medizin, Universitätsmedizin der Georg-August-Universität, 37099 , Göttingen

    B. Chapuy &  L. Trümper

  2. Klinik I für Innere Medizin der Universität zu Köln

    P. Borchmann & A. Engert

Authors
  1. B. Chapuy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Borchmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Trümper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Trümper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chapuy, B., Borchmann, P., Engert, A. et al. Targeted-Therapie. Onkologe 12, 651–658 (2006). https://doi.org/10.1007/s00761-006-1059-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-006-1059-x

Schlüsselwörter

Keywords

Search

Navigation